PCSK9: a promising therapeutic target for dyslipidemias?
作者信息
Lambert Gilles, Krempf Michel, Costet Philippe
机构信息
University of Nantes, Medical School, INSERM U539, CHU Hôtel-Dieu, 3(e) Nord, 1 Place Alexis Ricordeau, F-44093 Nantes cedex 1, France.
出版信息
Trends Endocrinol Metab. 2006 Apr;17(3):79-81. doi: 10.1016/j.tem.2006.02.001. Epub 2006 Feb 17.
PMID:16487721
Abstract
PCSK9 is the third gene to be implicated in autosomal dominant hypercholesterolemia. The recent discovery of mutations in PCSK9 protein associated with low plasma low-density lipoprotein in humans, the characterization of PCSK9-deficient mice hypersensitive to statins and the severely pathological phenotype of D374Y PCSK9-mutated patients shed a new light on this gene: is it a promising therapeutic target for dyslipidemias?
摘要
Zotero 插件